资金流向方面，主力资金净流入298.89万元，大单买入707.65万元，占比16.08%，卖出408.75万元，占 比9.29%。 康泰医学今年以来股价涨21.69%，近5个交易日涨2.27%，近20日涨1.22%，近60日涨11.81%。 今年以来康泰医学已经1次登上龙虎榜，最近一次登上龙虎榜为7月25日，当日龙虎榜净买入6861.01万 元；买入总计1.50亿元 ，占总成交额比27.22%；卖出总计8151.24万元 ，占总成交额比14.78%。 资料显示，康泰医学系统(秦皇岛)股份有限公司位于河北省秦皇岛市经济技术开发区秦皇西街112号， 成立日期1996年7月9日，上市日期2020年8月24日，公司主营业务涉及从事医疗诊断、监护设备的研 发、生产和销售。主营业务收入构成为：院线类产品47.54%，家用类产品41.01%，其他产品11.45%。 10月10日，康泰医学盘中上涨2.15%，截至10:38，报16.66元/股，成交4400.49万元，换手率1.06%，总 市值66.94亿元。 康泰医学所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、体外诊断、 抗原检测、幽门螺杆概念 ...

万泰生物所属申万行业为：医药生物-生物制品-疫苗。所属概念板块包括：体外诊断、抗原检测、猴痘 概念、幽门螺杆概念、疫苗等。 截至6月30日，万泰生物股东户数3.84万，较上期增加24.00%；人均流通股32958股，较上期减少 19.36%。2025年1月-6月，万泰生物实现营业收入8.44亿元，同比减少38.25%；归母净利润-1.44亿元， 同比减少155.30%。 分红方面，万泰生物A股上市后累计派现15.41亿元。近三年，累计派现13.11亿元。 机构持仓方面，截止2025年6月30日，万泰生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2275.44万股，相比上期增加515.08万股。华泰柏瑞沪深300ETF（510300）位居第九大流 通股东，持股672.44万股，相比上期增加71.58万股。易方达沪深300医药ETF（512010）位居第十大流 通股东，持股622.30万股，相比上期减少50.92万股。招商国证生物医药指数A（161726）退出十大流通 股东之列。 10月9日，万泰生物盘中上涨2.05%，截至11:01，报57.71元/股，成交1.59亿元，换手率0.22%，总 ...

9月26日，诺唯赞盘中上涨2.03%，截至13:48，报23.13元/股，成交3811.18万元，换手率0.42%，总市值 92.00亿元。 资料显示，南京诺唯赞生物科技股份有限公司位于江苏省南京经济技术开发区科创路红枫科技园D2 栋，成立日期2012年3月16日，上市日期2021年11月15日，公司主营业务涉及围绕酶、抗原、抗体等功 能性蛋白及高分子有机材料进行技术研发和产品开发的生物科技企业,依托于自主建立的关键共性技术 平台,先后进入了生物试剂、体外诊断业务领域,并正在进行抗体药物的研发。主营业务收入构成为：生 物试剂81.86%，诊断试剂9.99%，耗材等材料3.15%，仪器设备2.96%，技术服务1.85%，其他0.18%。 诺唯赞所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：基因测序、抗原检 测、体外诊断、合成生物、小盘等。 截至6月30日，诺唯赞股东户数8596.00，较上期增加2.37%；人均流通股46269股，较上期减少2.31%。 2025年1月-6月，诺唯赞实现营业收入6.06亿元，同比减少6.63%；归母净利润312.94万元，同比减少 80.63%。 资金流向方 ...

9月26日，英科医疗盘中上涨2.01%，截至10:22，报37.54元/股，成交1.71亿元，换手率1.00%，总市值 245.81亿元。 资金流向方面，主力资金净流出745.45万元，特大单买入412.42万元，占比2.41%，卖出658.84万元，占 比3.86%；大单买入2395.34万元，占比14.02%，卖出2894.37万元，占比16.94%。 英科医疗今年以来股价涨49.08%，近5个交易日涨5.27%，近20日涨2.21%，近60日涨46.64%。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 英科医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医用耗材、智慧医疗、 抗原检测、医疗器械、跨境电商等。 截至6月30日，英科医疗股东户数6.00万，较上期减少2.96%；人均流通股7825股， ...

英科医疗今年以来股价涨46.94%，近5个交易日涨3.99%，近20日跌1.73%，近60日涨45.15%。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 9月25日，英科医疗盘中下跌2.01%，截至13:50，报37.00元/股，成交4.68亿元，换手率2.67%，总市值 242.27亿元。 资金流向方面，主力资金净流出1567.62万元，特大单买入1279.07万元，占比2.73%，卖出2541.32万 元，占比5.43%；大单买入8113.51万元，占比17.34%，卖出8418.87万元，占比17.99%。 截至6月30日，英科医疗股东户数6.00万，较上期减少2.96%；人均流通股7825股，较上期增加3.07%。 2025年1月-6月，英科医疗实现营业收入49.13亿元，同比增长8.90%；归母净利润7.10亿 ...

Company Overview - Beijing Hotgen Biotech Co., Ltd. is located in Daxing District, Beijing, and was established on June 23, 2005. The company went public on September 30, 2019. Its main business involves the research, development, production, and sales of in vitro diagnostic reagents and instruments [1][2]. Financial Performance - For the first half of 2025, Hotgen Biotech reported operating revenue of 204 million yuan, a year-on-year decrease of 18.04%. The net profit attributable to shareholders was -83.998 million yuan, a year-on-year decrease of 93.24% [2]. - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 17.344 million yuan distributed over the past three years [3]. Stock Performance - As of September 24, Hotgen Biotech's stock price increased by 2.03%, reaching 182.98 yuan per share, with a total market capitalization of 16.964 billion yuan. The stock has risen 195.89% year-to-date, with a recent 5-day increase of 0.99% and a 20-day decrease of 13.68% [1]. - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 4, where it recorded a net purchase of 47.8269 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 6,938, a rise of 4.14%. The average number of circulating shares per person decreased by 3.74% to 13,362 shares [2]. - Among the top ten circulating shareholders, new entrants include Huatai-PineBridge Innovation Medical Mixed A and ICBC Frontier Medical Stock A, holding 2.8091 million shares and 1.5001 million shares, respectively [3].

Company Overview - Qianhong Biopharma Co., Ltd. is located in Changzhou, Jiangsu Province, established on April 30, 2003, and listed on February 18, 2011. The company specializes in the research, production, and sales of various pharmaceutical products, including lyophilized powder, lyophilized powder injections (including anti-tumor drugs), small-volume injections, tablets, hard capsules, granules, and raw materials [2]. Financial Performance - For the first half of 2025, Qianhong Biopharma achieved operating revenue of 862 million yuan, representing a year-on-year growth of 0.72%. The net profit attributable to the parent company was 258 million yuan, showing a significant year-on-year increase of 41.17% [2]. - The company has distributed a total of 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the past three years [3]. Stock Performance - As of September 23, Qianhong Biopharma's stock price was 9.38 yuan per share, with a market capitalization of 12.005 billion yuan. The stock has increased by 54.20% year-to-date but has seen a decline of 5.44% over the past five trading days and 12.42% over the past 20 days [1]. - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]. Shareholder Information - As of June 30, 2025, Qianhong Biopharma had 72,800 shareholders, an increase of 27.00% from the previous period. The average circulating shares per person decreased by 22.62% to 12,934 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 29.1651 million shares, a decrease of 11.9864 million shares from the previous period [3]. Business Segments - The company's main business revenue composition includes 62.97% from formulation series and 36.70% from raw material series, with other contributions at 0.33% [2]. - Qianhong Biopharma operates within the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, and is involved in various concept sectors such as heparin, ursodeoxycholic acid, antigen detection, medical devices, and biomedicine [2].

Company Overview - Steady Medical is located in Longhua District, Shenzhen, Guangdong Province, and was established on August 24, 2000. The company went public on September 17, 2020. Its main business involves the research, production, and sales of cotton products [1] - The company's revenue composition includes: consumer products - wet and dry cotton towels 19.87%, medical consumables - surgical room consumables 18.15%, medical consumables - traditional wound care and dressing products 13.88%, consumer products - sanitary napkins 13.02%, consumer products - adult clothing 12.73%, consumer products - baby clothing and supplies 11.36%, consumer products - other fiber products 5.24%, consumer products - other non-woven products 4.88%, and others 0.87% [1] Financial Performance - As of June 30, 2025, Steady Medical achieved operating revenue of 5.296 billion yuan, representing a year-on-year growth of 31.31%. The net profit attributable to the parent company was 492 million yuan, with a year-on-year increase of 28.07% [2] - Since its A-share listing, the company has distributed a total of 2.875 billion yuan in dividends, with 1.729 billion yuan distributed in the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders of Steady Medical was 27,900, an increase of 30.38% compared to the previous period. The average number of circulating shares per person was 6,290, a decrease of 23.30% [2] - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 7.4347 million shares as a new shareholder. The second-largest shareholder is E Fund Growth Enterprise Board ETF, holding 4.5371 million shares, a decrease of 113,400 shares compared to the previous period [3]

Group 1 - The stock price of Qianhong Biopharma fell by 2.05% on September 19, closing at 9.54 CNY per share, with a trading volume of 142 million CNY and a turnover rate of 1.56%, resulting in a total market capitalization of 12.209 billion CNY [1] - Year-to-date, Qianhong Biopharma's stock price has increased by 56.83%, but it has seen a decline of 5.36% over the last five trading days and 12.48% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on August 7, where it recorded a net purchase of 10.2288 million CNY [1] Group 2 - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province, and specializes in the production and sales of various pharmaceutical products, including lyophilized powder and injections [2] - The company's main business revenue composition includes 62.97% from formulations and 36.70% from raw materials, with other sources contributing 0.33% [2] - As of June 30, 2025, Qianhong Biopharma reported a revenue of 862 million CNY, a year-on-year increase of 0.72%, and a net profit attributable to shareholders of 258 million CNY, reflecting a growth of 41.17% [2] Group 3 - Since its A-share listing, Qianhong Biopharma has distributed a total of 1.862 billion CNY in dividends, with 453 million CNY distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 29.1651 million shares, a decrease of 11.9864 million shares from the previous period [3]

9月12日，长荣股份盘中上涨2.10%，截至09:53，报8.26元/股，成交4083.95万元，换手率1.60%，总市 值35.00亿元。 截至9月10日，长荣股份股东户数3.06万，较上期减少3.80%；人均流通股10251股，较上期增加3.95%。 2025年1月-6月，长荣股份实现营业收入7.26亿元，同比减少3.80%；归母净利润502.47万元，同比增长 156.45%。 分红方面，长荣股份A股上市后累计派现8.27亿元。近三年，累计派现0.00元。 责任编辑：小浪快报 今年以来长荣股份已经3次登上龙虎榜，最近一次登上龙虎榜为7月15日，当日龙虎榜净买入-1.21亿 元；买入总计6312.38万元 ，占总成交额比4.78%；卖出总计1.84亿元 ，占总成交额比13.94%。 资料显示，天津长荣科技集团股份有限公司位于天津市北辰经济开发区双辰中路11号，成立日期1995年 9月13日，上市日期2011年3月29日，公司主营业务涉及印刷包装设备的研发、制造和销售。主营业务收 入构成为：装备制造及系统解决方案88.31%，融资租赁4.86%，经营租赁4.59%，其他(补充)1.28%，健 康业务0.96 ...